LOS ANGELES--(BUSINESS WIRE)--Proneuron Biotechnologies Inc. today announced the initiation of a program to develop Proneuron's PN277 neuro-restorative therapy for Parkinson's disease (PD). The goal is to examine the ability of PN277 to prevent degeneration of dopaminergic neurons and/or to reverse dopamine loss in relevant preclinical models. PN277 is an oligopeptide that has been found to have significant immune-mediated neuro-restorative activities.
